Skip to main content
Top
Published in: Familial Cancer 3/2021

01-07-2021 | Thyroidectomy | Short Communication

A novel germline variant in RET gene resulting in an additional cysteine in a family with familial medullary thyroid carcinoma

Authors: Josep Oriola, Aurora Sanchez, Blanca Paniello, Jordi Puig de la Bellacasa, Josefina Biarnés

Published in: Familial Cancer | Issue 3/2021

Login to get access

Abstract

Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant inherited disease, characterized by germ-line variants in RET proto-oncogene. Variants are frequently located in the RET extracellular cysteine-rich region domain, mainly affecting cysteines which are replaced by an alternative amino acid, resulting in a mispaired cysteine and the generation of RET dimers. We describe a novel c.1765A > T variant of RET proto-oncogene in a family with medullary thyroid carcinoma (MTC) that predicts the creation of an additional cysteine p.(Ser589Cys) in the cysteine-rich domain. In this site only three other punctual variants have been described, giving rise to extra cysteines. We have characterized the clinical phenotype of this family. The index case was a 79-year-old woman with MTC in both thyroid lobes. This variant co-segregates in this family in four affected members. One member was operated on at 31 years of age and already presented MTC, indicating that prophylactic thyroidectomy was appropriated. Variants predicting additional cysteines are not frequent in RET, and when present, they allow us to understand their implication in the disease. According to clinical data obtained in this family, this variant could be categorized as a moderate-risk of the disease.
Literature
1.
go back to reference Wells SA Jr, Asa SL, Dralle H et al (2015) American Thyroid Association guidelines task force on medullary thyroid carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567–610CrossRef Wells SA Jr, Asa SL, Dralle H et al (2015) American Thyroid Association guidelines task force on medullary thyroid carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567–610CrossRef
2.
go back to reference Santoro M, Melillo RM, Carlomagno F et al (2004) Minireview: RET: normal and abnormal functions. Endocrinology 145(12):5448–5451CrossRef Santoro M, Melillo RM, Carlomagno F et al (2004) Minireview: RET: normal and abnormal functions. Endocrinology 145(12):5448–5451CrossRef
3.
go back to reference Wagner SM, Zhu S, Nicolescu AC et al (2012) Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2. Clinics 67(Suppl 1):77–84CrossRef Wagner SM, Zhu S, Nicolescu AC et al (2012) Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2. Clinics 67(Suppl 1):77–84CrossRef
4.
go back to reference Da Silva AM, Maciel RM, Da Silva MR et al (2003) A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88(11):5438–5443CrossRef Da Silva AM, Maciel RM, Da Silva MR et al (2003) A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88(11):5438–5443CrossRef
5.
go back to reference Oriola J, Halperin I, Rivera-Fillat F et al (2002) The finding of a somatic deletion in RET exon 15 clarified the sporadic nature of a medullary thyroid carcinoma suspected to be familial. J Endocrinol Invest 25:25–31CrossRef Oriola J, Halperin I, Rivera-Fillat F et al (2002) The finding of a somatic deletion in RET exon 15 clarified the sporadic nature of a medullary thyroid carcinoma suspected to be familial. J Endocrinol Invest 25:25–31CrossRef
6.
go back to reference Cosci B, Vivaldi A, Romei C, et al (2011) In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr Relat Cancer 18(5):603–612CrossRef Cosci B, Vivaldi A, Romei C, et al (2011) In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr Relat Cancer 18(5):603–612CrossRef
7.
go back to reference Höppner W, Ritter MM (1997) A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 6(4):587–90CrossRef Höppner W, Ritter MM (1997) A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 6(4):587–90CrossRef
8.
go back to reference Ahmed SA, Snow-Bailey K, Highsmith WE et al (2005) Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases. J Mol Diagn 7:283–288CrossRef Ahmed SA, Snow-Bailey K, Highsmith WE et al (2005) Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases. J Mol Diagn 7:283–288CrossRef
9.
go back to reference Huguet I, Cranston T, Walker L et al (2014) A patient with an apparently sporadic pheochromocytoma with a rearranged during transfection codon 635 variant: a mild form of multiple endocrine neoplasia type 2? Endocr Pract 20(4):e65-8CrossRef Huguet I, Cranston T, Walker L et al (2014) A patient with an apparently sporadic pheochromocytoma with a rearranged during transfection codon 635 variant: a mild form of multiple endocrine neoplasia type 2? Endocr Pract 20(4):e65-8CrossRef
10.
go back to reference Voss RK, Feng L, Lee JE et al (2017) Medullary thyroid carcinoma in MEN2A: ATA moderate- or high-risk RET mutations do not predict disease aggressiveness. J Clin Endocrinol Metab 102(8):2807–2813CrossRef Voss RK, Feng L, Lee JE et al (2017) Medullary thyroid carcinoma in MEN2A: ATA moderate- or high-risk RET mutations do not predict disease aggressiveness. J Clin Endocrinol Metab 102(8):2807–2813CrossRef
Metadata
Title
A novel germline variant in RET gene resulting in an additional cysteine in a family with familial medullary thyroid carcinoma
Authors
Josep Oriola
Aurora Sanchez
Blanca Paniello
Jordi Puig de la Bellacasa
Josefina Biarnés
Publication date
01-07-2021
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2021
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-020-00214-0

Other articles of this Issue 3/2021

Familial Cancer 3/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine